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ABSTRACT	Thyroid	eye	disease	(TED)	is	a	potentially	sight-threatening	and	cosmetically	disfiguring	condition	arising	in	25-50%	of	patients	with	Graves'	hyperthyroidism.	CIRTED	is	the	first	study	to	evaluate	the	long-term	role	of	radiotherapy	and	prolonged	immunosuppression	with	azathioprine	in	treating	TED,	one	aim	of	which	was	to	validate	the	use	of	the	English	version	of	GO-QOL	in	an	UK	population	with	TED.	In	a	three	stage	design	over	a	48	week	period,	the	GO-QOL	was	tested	and	compared	to	a	general	measure	of	quality	of	life	(WHOQOL-Bref).	In	stage	1	utilising	a	standard	14	day	test-retest	design	both	GO-QOL	subscales	achieved	Cronbach’s	alphas	demonstrating	excellent	validity	and	internal	reliability	(Visual	Function	0.929	and	0.931;	Appearance	0.888	and	0.906).	In	stage	2,	Repeated	Measures	ANOVA	demonstrated	longitudinal	validity,	with	both	subscales	of	the	GO-QOL	showing	significant	change	over	time	(Visual	Function,	p<.001;	Appearance,	p<.002).	In	stage	3	the	GO-QOL	showed	discriminant	validity	at	the	week	48	time	point,	with	the	visual	function	subscale	being	able	to	detect	changes	in	groups	identified	by	clinicians	(using	BCCOM	ratings	of	improvement	or	deterioration),	while	both	subscales	could	detect	group	differences	when	based	on	participants’	subjective	ratings	of	TED	noticeability	and	severity.	The	results	of	this	project	provide	support	for	the	English	translation	of	the	GO-QOL	as	an	outcome	measure	for	patients	with	moderately	severe	active	Graves'	orbitopathy/TED.		
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INTRODUCTION		Graves’	ophthalmopathy	or	orbitopathy	(GO)	also	known	as	thyroid	eye	disease	(TED)	is	a	potentially	sight-threatening	and	cosmetically	disfiguring	condition	arising	in	25-50%	of	patients	with	Graves'	hyperthyroidism	(Bahn	&	Heufelder,	1993).	The	condition	is	rare	and	causes	redness	and	grittiness	of	the	eye	and	can	lead	to	disfiguring	swelling	of	the	eyelids,	proptosis	(abnormal	protrusion	or	displacement	of	the	eye)	and	even	blindness	(Weetman,	1991).	GO	is	an	autoimmune	disorder,	linked	to	thyroid	autoimmunity	by	autoantigens	shared	between	the	thyroid	and	the	orbit	of	the	eye	
(Perros,	Crombie	&	Kendall-Taylor,	1995).		Inflammatory	processes	are	activated	and	fibroblasts	in	the	eyes’	orbital	tissue	become	stimulated	leading	to	orbital	tissue	swelling,	hyaluronan	production,	and	expansion	of	the	extraocular	muscles,	retro-orbital	fat	and	connective	tissues	(Khoo	&	Bahn,	2007).	
	 	Currently	the	management	of	GO/TED	is	considered	suboptimal,	and	available	treatments	do	not	specifically	target	the	underlying	pathogenic	process	(Bartalena	et	al,	2016).	The	Combined	Immunosuppression	and	Radiotherapy	in	Thyroid	Eye	Disease	(CIRTED)	trial	was	designed	to	assess	the	effect	of	using	radiotherapy	and	the	immunosuppressive	drug	azathioprine	in	combination	with	standard	prednisolone	treatment	(Rajendram	et	al,	2008).	CIRTED	is	the	first	study	to	evaluate	the	long-term	role	of	radiotherapy	and	prolonged	immunosuppression	with	azathioprine	in	treating	GO/TED.			It	is	well	established	that	TED	can	have	a	major	impact	on	quality	of	life,	in	particular	disfiguring	changes	to	the	eyes	and	face	which	can	have	a	direct	impact	on	psychological	health	(Coulter,	Frewin,	Krassas	&	Perros,	2007).	As	the	aim	of	treating	GO/TED	is	to	improve	patients’	visual	function	as	well	as	making	them	look	and	feel	better,	it	is	important	to	assess	the	patients’	perception	of	these	markers	as	part	of	a	clinical	trial.	The	GO-QOL	questionnaire	was	developed	by	Terwee,	Gerding,	Dekker,	Prummel	&	Wiersinga	(1998)	as	a	TED	specific	quality	of	life	questionnaire	that	can	be	used	as	an	outcome	measure	for	studies	and	may	also	be	of	use	in	clinical	practice.	Marcocci	et	al	(2011)	tested	the	use	of	selenium	in	mild	GO	and	used	the	GO-QOL	to	evaluate	quality	of	life	outcomes.	They	showed	a	correlation	that	indicated	that	as	participants’	improved	with	selenium	treatment	their	quality	of	life	also	improved,	as	measured	by	the	GO-QOL.	However,	to	our	knowledge,	the	CIRTED	trial	would	be	the	first	time	that	the	measure	has	been	used	in	a	population	with	moderately	active	TED	being	treated	in	a	secondary	care	setting.		The	aim	of	this	three	stage	project	was	to	validate	the	use	of	the	English	version	of	GO-QOL	 in	an	UK	population	with	TED.	The	GO-QOL	has	been	 translated	 from	Dutch;	 the	Dutch	version	has	previously	been	validated	in	the	Netherlands	(Terwee	et	al,	1999).	In	the	first	stage	of	the	work,	the	internal	validity	and	test-retest	study,	the	objective	was	
to	 assess	 the	 consistency	 of	 the	 GO-QOL	 in	 measuring	 functional	 and	 appearance-related	 issues	 resulting	 from	TED	over	a	14	day	period	where	 the	 expectation	 is	 that	scores	on	both	administrations	should	be	correlated.			In	the	second	stage,	we	measured	longitudinal	validity	i.e.	the	responsiveness	of	the	GO-QOL	to	changes	in	TED	post-treatment	against	a	more	general	measure	of	quality	of	life	(in	 this	 case,	 the	 WHOQOL-Bref;	 The	 WHOQOL	 Group,	 1998).	 This	 work	 had	 two	aspects:		1. If	the	GO-QOL	is	valid	(i.e.	sensitive	to	changes	in	visual	functioning	and	appearance	as	a	 result	of	TED)	we	would	expect	 larger	effect	sizes	 for	 the	GO-QOL	than	 for	 the	general	quality	of	life	measure	(WHOQOL-Bref).				2. Furthermore,	 changes	 in	 clinical	 characteristics	 relating	 to	 visual	 functioning	 and	appearance,	as	indicated	by	transitional	variables,	should	be	more	closely	associated	with	 changes	 in	 scores	 on	 the	 relevant	 subscales	 of	 the	 GO-QOL	 than	 with	 the	WHOQOL-Bref.		The	third	and	final	stage	was	to	explore	the	extent	to	which	the	GO-QOL	can	demonstrate	discriminant	validity.	That	is,	whether	the	GO-QOL	can	distinguish	between	patient	populations	based	on	either	clinician	ratings	of	improvement	or	participants’	subjective	measures.	Although	it	should	be	noted	that	subjective	severity	does	not	always	correlate	well	with	objective	measures	of	disease	and	physicians’	assessments	(Bessell,	Dures,	Semple	&	Jackson,	2012).	
	
METHODS	
Design	
The study protocol has been described in detail previously	(Rajendram	et	al	2008).	In	brief,	CIRTED	is	a	factorial	design,	double-masked,	multi-centre,	randomised	controlled	trial	(see	Figure	1	for	a	diagram	of	the	trial	design).		
		
Figure	1.	Trial	design,	study	group	allocation.			
Materials	(see	also	Table	1)	The	Graves'	ophthalmopathy	quality	of	life	assessment	(GO-QOL)	questionnaire	consists	of	two	subscales,	each	comprising	eight	questions,	on	visual	function	and	the	psychological	impact	of	changed	appearance	(Terwee	et	al,	1998).			The	WHOQOL-Bref	is	a	widely	used	and	previously	validated	measure	of	quality	of	life	consisting	of	28	items	which	cover	subjective	overall	quality	of	life	and	subjective	overall	health,	plus	items	relating	to	domains	of	physical,	psychological,	social	relationships	and	environment	(The	WHOQOL	Group,	1998).	The	WHOQOL-Bref	has	been	widely	used	with	a	range	of	populations	and	is	reported	to	have	good	psychometric	properties	(Skevington,	Lotfy	&	O’Connell,	2004).		Two	transitional	variables	relating	closely	to	the	subscales	of	the	GO-QOL	were	included	at	follow	up	as	an	external	standard	to	identify	changes	post-treatment	(labelled	“T1”	and	“T2”).	These	variables	were	agreed	with	the	authors	of	the	GO-QOL	as	being	suitable	for	this	purpose.	In	order	to	explore	the	impact	of	TED	and	its	treatment	on	psychological	adjustment	and	daily	functioning	more	broadly,	Visual	Analogue	Scales	(VAS)	were	also	included	in	the	study.	VAS	scales	are	easy	for	respondents	to	complete	and	are	often	used	in	clinical	assessments	(Carr,	1997).		
Clinician	ratings	of	disease	severity	and	activity	were	also	included.	The	Binary	Composite	Outcome	Score	(BCCOM)	a system of major and minor criteria used in previous 
TED trials (Prummel et al, 2004; Marcocci et al, 2001; Mourits et al, 2000).	It	is	a	clinician	rating	of	improvement	in	the	CIRTED	trial	used	at	1	year	post	treatment	to	classify	study	participants’	treatment	as	being	successful	or	not.			
Table	1.	Overview	of	the	standardised	questionnaires.		
Measure	 Description	
Standardised	questionnaires	GO-QOL	(Terwee	et	al,	1998)	 -	TED	specific	quality	of	life	measure,	validated	in	the	Netherlands	-	2	subscales:	‘visual	function’	&	‘appearance’	comprising	8	questions	each	-	each	item	is	scored	as	follows:	1=	not	impaired;	2=a	little	impaired;	3=severely	impaired	-	raw	scores	are	transformed	to	give	a	total	out	of	100	for	each	subscale	-		higher	scores	indicate	greater	quality	of	life		WHO-QOL-Bref	(The	WHOQOL	Group,	1998)	
-	general	quality	of	life	measure,	validated	for	use	in	the	UK	-	4	subscales:	psychological,	physical,	social	and	environmental;	28	questions	in	total	-	scored	on	a	5-point	Likert	scale	-	raw	scores	are	transformed	to	give	a	total	out	of	100	for	each	subscale	-	higher	scores	indicate	greater	satisfaction	with	life		
Transitional	variables	T1	 -	is	a	single	item:	“My	eye	condition	causes	me	physical	pain/discomfort”	-	scored	as	follows:	1=	never/almost	never;	2=sometimes;	3=often;	4=almost	always	
	
Protocol	&	Participants	All	participants	referred	to	a	trial	centre	during	the	duration	of	the	study	were	considered	for	inclusion.	Participants	were	prescribed	a	high	dose	of	tapering	prednisolone	at	their	initial	enrolment	visit.	If	they	were	eligible,	responded	to	steroids	and	not	excluded,	participants	were	randomized	into	one	of	four	trial	arms	(see	Figure	1,	Table	2,	and	CIRTED	study	protocol	–	Rajendram	et	al,	2008).			
T2	 -	is	a	single	item:	“My	eye	condition	limits	my	physical	ability	to	do	the	things	I	want	to	do”	-	each	item	is	scored	as	follows:	1=	never/almost	never;	2=sometimes;	3=often;	4=almost	always	
Visual	Analogue	Scales	Noticeability		 -	is	a	single	item:	“How	noticeable	do	you	feel	your	thyroid	eye	disease	is	to	other	people?”	-	scored	on	a	10	cm	line	with	the	following	anchors:	Not	at	all	noticeable	|..........|	Very	noticeable	-	scored	0-10	-	higher	scores	indicate	greater	distress		Severity	 is	a	single	item:	“How	severe	do	you	feel	your	thyroid	eye	disease	is?”	-	scored	on	a	10	cm	line	with	the	following	anchors:	Not	very	severe	|..........|	Extremely	severe	-	scored	0-10	-	higher	scores	indicate	greater	distress		
Clinical	rating	Binary	Composite	Outcome	Score	(BCCOM)	
-	clinician-rating	-	binary	composite	outcome	score	with a positive result 
(improvement with no concomitant deterioration) versus no 
change or any deterioration	-	deteriorated	(-1),	improved	(1)	
For	validating	test-retest	reliability,	participants	completed	the	GO-QOL	twice	at	a	two-week	interval,	time	point	1	(-2	weeks,	i.e.	enrolment	into	the	study)	and	time	point	2	(0	weeks,	i.e.	randomization	into	the	study).	Two	weeks	have	previously	been	used	by	Terwee	et	al	(1999)	for	assessing	test-retest	reliability,	as	it	is	long	enough	to	avoid	recall	bias	and	short	enough	for	patients	not	to	experience	clinically	important	changes	in	their	condition.	Data	from	participants	for	the	longitudinal	validity	testing	was	collected	at	all	four	time	points.			
Table	2.	Data	collection	time	points	and	their	relation	to	participant	trial	
appointments,	plus	study	measures	used	at	each	time	point,	and	number	of	
potential	participants	attending	each	appointment	(N)	
	 	 Trial	
Appointment	
Study	measures	 N	
St
ud
y	
tim
e	
po
in
ts
	
1	 -2	weeks	Enrolment		 GO-QOL,	WHO-QOL,	VAS,		demographic	data	 157	
2	 0	weeks	Randomization		 GO-QOL	 133	
3	 12	weeks	Short	term	 GO-QOL,	WHO-QOL,	transition	variables,	VAS	 108	
4	 48	weeks	Long	term	 GO-QOL,	WHO-QOL,	transition	variables,	VAS,	BCCOM	
102	
	
	
RESULTS	The	results	are	reported	in	the	three	stages	that	the	work	was	undertaken.	All	analyses	were	undertaken	using	SPSS	version	22.	
	
Stage	1	GO-QOL	validation:	internal	validity	and	test	re-test	157	participants	attended	for	study	enrolment,	while	133	attended	the	randomization	appointment.	Of	these,	142	participants	completed	the	GO-QOL	at	study	enrolment,	and	126	completed	the	GO-QOL	at	randomization	(see	Table	3).		
	Table	3.	Participant	characteristics	for	Stage	1	GO-QOL	Validation:	internal	validity	
and	test	re-test	
	 Study	time	point	
Variable	 Enrolment	(-2	weeks)	 Randomization	(week	0)	
Sample	size	 142	 126	
Age	 48.02±11.44	 48.27±11.40	
Sex	(male/female)	 41/101	
		34/92	
Ethnicity	 	 	Caucasian/Black	 99/16	 87/14	Asian/Oriental	 11/4	 10/4	Other	(or	not	stated)	 12	 11		Item	response	tables	for	time	points	1	(-2	weeks,	enrolment)	and	2	(0	weeks,	randomisation)	were	generated	to	identify	patterns	of	responses	and	are	shown	in	Tables	4	&	5.		
	
Table	4.	Item	response	table	for	GO-QOL	at	time	point	1	(-2	weeks,	enrolment).	
	
N	
Min	
score	
Max	
score	
Mean	
score	
SD	
Visual	Function	subscale	VF1	Cycling	 87	 1	 3	 2.43	 0.80	VF2	Driving	 103	 1	 3	 2.19	 0.81	VF3	Walking	indoors	 139	 1	 3	 2.71	 0.54	VF4	Walking	outdoors	 141	 1	 3	 2.49	 0.64	VF5	Reading	 140	 1	 3	 2.01	 0.70	VF6	Watching	TV	 141	 1	 3	 2.12	 0.68	VF7	Hobbies	 122	 1	 3	 2.29	 0.77	VF8	Interference	with	daily	life	 141	 1	 3	 2.10	 0.77	
Appearance	subscale	
App9	Change	in	appearance	 142	 1	 3	 1.42	 0.54	App10	Feeling	watched	 142	 1	 3	 2.14	 0.77	App11	Unpleasant	reactions	 140	 1	 3	 2.49	 0.68	App12	Impact	on	self-confidence	 142	 1	 3	 1.73	 0.72	App13	Feeling	of	social	isolation	 142	 1	 3	 2.50	 0.69	App14	Influence	on	friendships	 142	 1	 3	 2.46	 0.73	App15	Less	often	in	photos	 141	 1	 3	 1.90	 0.85	App16	Camouflaging	appearance	 142	 1	 3	 2.04	 0.82	Key:	N=	number	of	responses;	SD	=	standard	deviation		
Table	5.	Item	response	table	for	GO-QOL	at	time	point	2	(week	0,	randomisation)		
	
N	
Min	
Score	
Max	
Score	
Mean	
score	
SD	
Visual	Function	subscale	VF1	Cycling	 75	 1	 3	 2.59	 0.68	VF2	Driving	 93	 1	 3	 2.38	 0.75	VF3	Walking	indoors	 125	 1	 3	 2.72	 0.47	VF4	Walking	outdoors	 127	 1	 3	 2.61	 0.61	VF5	Reading	 127	 1	 3	 2.23	 0.69	VF6	Watching	TV	 126	 1	 3	 2.36	 0.66	VF7	Hobbies	 110	 1	 3	 2.47	 0.69	VF8	Interference	with	daily	life	 127	 1	 3	 2.28	 0.73	
Appearance	subscale	App9	Change	in	appearance	 126	 1	 2	 1.50	 0.50	App10	Feeling	watched	 126	 1	 3	 2.17	 0.76	App11	Unpleasant	reactions	 125	 1	 3	 2.58	 0.60	App12	Impact	on	self-confidence	 126	 1	 3	 1.83	 0.75	App13	Feeling	of	social	isolation	 126	 1	 3	 2.59	 0.65	App14	Influence	on	friendships	 126	 1	 3	 2.45	 0.77	App15	Less	often	in	photos	 126	 1	 3	 2.01	 0.83	App16	Camouflaging	appearance	 126	 1	 3	 2.05	 0.81	Key:	N=	number	of	responses;	SD	=	standard	deviation		
Not	all	participants	cycled	or	drove,	hence	the	lower	number	of	responses	to	questions	1	and	2	on	the	Visual	Function	subscale	at	both	time	points.	As	per	the	questionnaire	authors’	instructions	(Terwee	et	al,	1998),	adjustments	for	missing	data	were	made	when	totalling	the	raw	scores	for	each	subscale	prior	to	transforming	them	into	a	total	score	out	of	100	for	subsequent	analyses.	Internal	validity	was	assessed	using	Cronbach’s	alpha	calculations;	at	time	1	(-2	weeks,	enrolment)	the	visual	function	subscale	achieved	a	Cronbach’s	alpha	score	of	0.929	(CI	0.909	–	0.944)	while	the	appearance	subscale	recorded	0.888	(CI	0.857	–	0.912).	At	time	2	(week	0,	randomization),	the	alpha	results	for	visual	function	remained	virtually	unchanged	at	0.931	(CI	0.912	–	0.946),	while	the	appearance	subscale	improved	slightly	to	0.906	(CI	0.880	–	0.926).	This	indicates	good	internal	validity	of	the	subscales	at	both	time	points,	with	values	over	0.7	generally	acceptable	for	psychometric	questionnaires	(BPS,	1992),	and	all	alphas	falling	with	the	range	of	the	calculated	confidence	intervals.			Intraclass	correlation	coefficients	for	both	subscales	were	found	to	be	highly	significant	(visual	function,	r=0.774,	p<.001;	appearance,	r=0.862,	p<.001),	indicating	the	robust	test-retest	reliability	of	the	GO-QOL	subscales.		
Stage	2:	Longitudinal	validation	of	GO-QOL		Longitudinal	validation	was	performed	using	data	from	the	127	participants	that	were	randomised	into	the	trial	(Table	6).		
	
Table	6.	CIRTED	trial	allocation	groups.	
Group	 Allocation	 N=127	randomised	1	 Radiotherapy	and	Azathioprine	 31	(24.4%)	2	 SHAM	Radiotherapy	and	Azathioprine	 30	(23.6%)	3	 Radiotherapy	and	PLACEBO	 32	(25.2%)	4	 SHAM	Radiotherapy	and	PLACEBO	 32	(25.2%)	
	In	this	second	stage,	we	measured	the	responsiveness	of	the	GO-QOL	to	changes	in	TED	post-treatment	against	the	WHOQOL-Bref	(a	more	general	measure	of	quality	of	life).	
We	hypothesized	that,	if	the	GO-QOL	is	sensitive	to	changes	in	visual	functioning	and	appearance	as	a	result	of	TED	we	would	expect	larger	effect	sizes	for	the	GO-QOL	than	for	the	general	measure	(WHOQOL-Bref).		Of	the	127	randomized	participants,	108	participants	provided	enough	completed	questionnaire	data	at	the	12	week	trial	appointment,	while	100	of	those	participants	who	attended	the	48	week	appointment	completed	the	study	measures	(see	Table	7).	
	
Table	7.	Participant	characteristics	for	Stage	2:	Longitudinal	validation	of	GO-QOL	
Variable	 Study	time	point	 		 Short	term	(12	weeks)	 Long	term	(48	weeks)	
N	 108	 101	
Age	 49.48±10.82	 49.88±10.46	
Sex	(male/female)	 29/79	 27/73	
Ethnicity	 	 	Caucasian/Black	 79/13	 72/10	Asian/Oriental	 8/4	 9/4	Other	(or	not	stated)	 4	 5		For	the	sake	of	completeness,	internal	validity	was	assessed	again	using	Cronbach’s	alpha	calculations;	at	both	time	3	(short	term	12	week	trial	appointment)	and	time	4	(long	term	48	week	appointment).	At	time	3	the	visual	function	subscale	achieved	a	Cronbach’s	alpha	score	of	0.904	(CI	0.854	–	0.937)	while	the	appearance	subscale	recorded	0.918	(CI	0.891	–	0.938).	At	time	4	the	alpha	result	for	visual	function	had	reduced	slightly	to	0.887	(CI	0.823	–	0.928),	while	the	appearance	subscale	remained	largely	unchanged	at	0.915	(CI	0.886	–	0.937).	As	before,	this	indicates	good	internal	validity	of	the	subscales	at	both	time	points	with	all	alphas	falling	with	the	range	of	the	calculated	confidence	intervals.			Repeated	measures	ANOVA	(with	time	as	3	level	factor,	i.e.	-2,	12,	and	48	weeks)	revealed	significant	changes	in	scores	for	both	GO-QOL	subscales	between	the	baseline	(data	collected	at	enrolment,	-2	weeks)	and	the	long	term	(48-week)	time	point	(Visual	
Function,	p=0.001,	Appearance,	p=0.002)	and	a	medium	effect	size	for	both	subscales	(Visual	Function,	η2=0.114;	Appearance,	η2=0.069).	Effect	sizes	for	the	WHO-QOL	subscales	were	small	with	the	exception	of	the	psychological	subscale	which	had	a	medium	effect	size	(psychological,	η2=0.064;	physical,	η2=0.037;	social,	η2=0.041;	environment,	η2=0.043).	As	expected,	the	GO-QOL	recorded	a	bigger	effect	size	than	the	WHOQOL-Bref	with	the	exception	of	the	psychological	subscale	(Table	8).		
Table	8:	Mean	scores	±	standard	deviations	for	G0-QOL	and	WHOQOL-Bref	across	
study	time	points,	results	for	RM	ANOVA	with	effect	sizes	
Study	measure	 Enrolment	
(-2	weeks)	
Short	term	
(12	weeks)	
Long	term	
(48	weeks)	
RM	ANOVA	
F	&	p	value	
Effect	size		η2	
Go-QoL	subscales:	Visual	Function	 65.94	±28.49	 72.49	±26.64	 76.11	±24.73	 11.034	p<0.001	 0.114	Medium	Appearance	 54.1		±26.54	 58.81	±27.25	 60.84	±28.75	 13.061	p<0.002	 0.069	Medium	
WHOQOL-Bref	subscales:	Physical	 58.69	±22.64	 60.93	±21.01	 63.46	±20.67	 3.18	p<0.044	 0.037	Small	Psychological	 52.66	±21.35	 52.14	±23.04	 57.79	±20.20	 6.53	p<0.002	 0.064	Medium	Environment	 66.60	±20.03	 67.81	±18.92	 69.15	±17.13	 1.97	p<0.143	 0.043	Small	Social	Relationships	 66.08	±20.81	 60.83	±21.53	 65.54	±21.77	 2.99	p<0.054	 0.041	Small			We	also	hypothesized	that	changes	in	clinical	characteristics	relating	to	visual	functioning	and	appearance,	as	indicated	by	the	transitional	variables,	should	be	more	closely	associated	with	changes	in	scores	on	the	relevant	subscales	of	the	GO-QOL	than	with	the	WHOQOL-Bref.	As	expected	since	all	study	participants	were	taking	steroid	treatment,	correlation	calculations	showed	positive	correlations	between	both	the	transitional	variables	(T1	and	T2)	and	the	GO-QOL	appearance	subscale	at	the	12-week	time	point,	while	the	Visual	Function	subscale	only	correlated	with	T1	(Table	9).	Similarly,	three	of	the	WHOQOL-Bref	subscales	significantly	correlated	with	T1,	while	all	four	subscales	significantly	correlated	with	T2.	At	48-weeks	significant	correlations	were	observed	only	for	the	appearance	subscale	of	the	GOQOL	with	the	transitional	variables.	
	We	also	included	two	Visual	Analogue	Scales	to	explore	the	impact	of	treatment	for	TED	on	psychological	adjustment	and	daily	functioning	more	broadly.	At	12	weeks	significant	correlations	were	observed	between	both	VAS	scales	and	the	appearance	subscale	of	the	Go-QoL.	Three	of	the	four	domains	of	the	WHOQOL-Bref	significantly	correlated	with	the	VAS	for	participant	perceived	noticeability	of	TED	(psychological,	physical	and	environment),	while	a	different	trio	of	domains	significantly	correlated	with	the	VAS	for	participant	ratings	of	severity	of	TED	(physical,	social	and	environment).	At	48	weeks,	the	only	significant	correlations	observed	were	between	both	VAS	scales	and	the	appearance	subscale	of	the	Go-QoL.	
	
Table	9.	Transition	scores	and	visual	analogue	scales	correlated	with	GO-QOL	and	
WHO-QOL	scores.	
	 T1	 T2	 VAS	Noticeability	 VAS	Severity	
Week	12	GO-QOL	subscales:	Visual	Function	-0.413**	 0.015	 					-0.108	 	-0.117	Appearance	 -0.409**	-0.580**	 -0.587**	 -0.552**	
Week	12	WHOQOL-Bref	subscales:	Psychological	 -0.284**	-0.475**	 -0.399**	 	-0.127	Physical	 -0.451**	-0.612**	 -0.383**	 -0.466**	Social	 	-0.193	 -0.307**							-0.167	 -0.262*	Environment	 -0.295**	-0.508**	 -0.346**	 -0.253**		 	 	 	 	
Week	48	GO-QOL	subscales:	Visual	Function	 -0.017	 -0.162	 0.014	 -0.046	Appearance	 -0.389**	-0.574**	 -0.723**	 -0.678**	
Week	48	WHOQOL-Bref	subscales:	Psychological	 0.19	 0.017	 -0.037	 0.148	Physical	 0.149	 -0.005	 -0.106	 -0.024	Social	 0.158	 0.083	 -0.151	 0.089	
Environment	 0.199	 0.025	 -0.07	 0.006	Key:	**	=	significant	at	p<.001,	*=	significant	at	p<.05		
Stage	3	Exploring	discriminant	validity	and	the	relationships	between	subjective	
and	objective	measures	of	disease	severity		The	third	and	final	stage	was	to	explore	the	discriminant	validity	of	the	GO-QOL	as	well	as	the	relationships	between	the	subjective	and	objective	clinical	measures	for	TED	used	in	this	study.		Clinician	ratings	on	BCCOM	at	the	48	week	time	point	were	used	to	split	participants	into	two	groups,	condition	has	deteriorated	(-1,	N=58)	or	improved	(+1,	N=36;	Table	10).	Analyses	were	then	undertaken	to	determine	any	differences	in	mean	GO-QOL	scores	between	these	groups.	It	might	be	expected	that	there	would	be	differences	between	the	mean	changes	(pre/post-treatment)	in	GO-QOL	scores	depending	on	whether	clinicians	reported	visual	functioning/appearance	having	either	deteriorated	or	improved;	i.e.	we	would	expect	larger	increases	in	scores	on	the	GO-QOL	for	participants	who	reported	an	improvement	compared	to	those	who	did	not.		
Table	10.	Participant	characteristics	for	Stage	3:	Exploring	discriminant	validity	
and	the	relationships	between	subjective	and	objective	measures	of	disease	severity	
Variable	 Study	time	point	48	weeks			 -1	deteriorated	 +1	improved	N	 58	 36	Age	 50.31±10.72	 48.72±10.53	Sex	(male/female)	 12/46	 12/24	
Ethnicity	 	 	Caucasian/Black	 46/4	 22/6	Asian/Oriental	 5/2	 4/1	Other/missing	 1/0	 3/0		
Splitting	the	cohort	according	to	BCCOM	outcomes	and	comparing	mean	GO-QOL	scores	between	the	groups	using	an	independent	samples	t-test	a	significant	difference	was	observed	for	the	Visual	Function	subscale	at	48-weeks	(p=0.006),	although	no	similar	statistically	significant	difference	was	seen	for	the	Appearance	subscale	at	the	same	time	point.	Similarly,	no	statistically	significant	differences	between	WHO-QOL	domain	scores	was	observed	for	the	BCCOM	groups	at	the	same	time	point.	(Table	11).		
Table	11.	Comparing	means	of	GO-QOL	&	WHOQoL	subscales	according	to	BCCOM	
group	at	48	week	time	point	
GO-QOL	 BCCOM	 Mean±sd	 p	Sig.	(2-tailed)	Visual	Function	 +1	(improved)		 83.06±21.06	 0.006		 -1(deteriorated)	 67.86±26.46	Appearance	 +1	(improved)		 64.89±28.33	 0.152	
	 -1	(deteriorate)	 55.89±28.26	
WHOQoL	 	 	 	Psychological	 +1	(improved)		 51.73±22.32	 0.138	
	 -1(deteriorated)	 59.61±19.29	Physical	 +1	(improved)		 58.08±22.27	 0.537	
	 -1(deteriorated)	 61.63±22.21	Social	 +1	(improved)		 56.30±23.75	 0.083		 -1(deteriorated)	 67.34±22.96	Environment	 +1	(improved)		 65.08±19.66	 0.356		 -1(deteriorated)	 69.74±19.68		The	cohort	was	also	split	in	relation	to	the	scores	achieved	on	the	two	Visual	Analogue	Scales,	where	5.1	was	used	as	the	cut	off	to	identify	those	of	the	100	(where	we	had	these	data	at	week	48)	who	rated	themselves	as	still	having	TED	that	was	either	noticeable	or	severe.	When	analysed	according	to	these	groupings,	the	subscale	domains	of	the	WHOQoL	still	showed	no	significant	differences,	but	in	relation	to	noticeability	of	TED	(where	participants	scored	5.1	or	over)	both	subscales	of	the	GO-QOL	showed	statistical	significantly	differences	(p<.001).	For	those	participants	who	judged	themselves	to	still	have	severe	TED	(i.e.	they	scored	5.1	or	over	on	the	VAS	for	
severity),	both	subscales	of	the	GO-QOL	showed	statistical	significantly	differences	(p<.001)	(Table	12).		
Table	12.	Comparing	means	of	GO-QOL	subscales	according	to	VAS	group	at	48	
week	time	point	
GO-QOL	 VAS	noticeability	 Mean±sd	 p	Sig.	(2-tailed)	Visual	Function	 <5.0	(improved,	n=45)		 84.63±20.72	 0.001		 >5.1(noticeable,	n=54)	 66.37±26.36	Appearance	 <5.0	(improved,	n=45)		 79.86±18.17	 0.001	
	 >5.1(noticeable,	n=55)	 45.23±25.11	
	 VAS	severity	 	 	Visual	Function	 <5.0	(improved,	n=53)		 84.00±20.46	 0.001	
	 >5.1(TED	severe,	n=45)	 64.54±26.71	Appearance	 <5.0	(improved,	n=53)		 74.29±23.14	 0.001	
	 >5.1(TED	severe,	n=46)	 46.06±25.60	
	So	it	would	seem	that	the	GO-QOL	does	indeed	demonstrate	discriminant	validity,	although	there	is	some	suggestion	in	these	data,	that	it	may	be	dependent	on	the	grouping	variable	utilised.	The	clinician	ratings	(BCCOM)	and	participant	subjective	ratings	(VAS	scales)	were	broadly	similar	in	their	results	for	the	Visual	Function	component	of	the	GO-QOL,	but	to	distinguish	in	relation	to	appearance	issues,	it	would	appear	that	using	participant	ratings	results	in	stronger,	statistically	significant	differences.	
	
	
DISCUSSION	The	results	of	this	project	support	both	the	internal	validity	and	reliability	of	the	English	translation	of	the	GO-QOL	as	an	outcome	measure	for	patients	with	moderately	active	Graves'	orbitopathy.	Longitudinal	validity	has	also	been	confirmed,	with	the	GO-QOL	being	more	sensitive	to	changes	in	TED	over	time	than	the	more	general	WHO-QOL-Bref.,	whilst	also	being	associated	with	generally	larger	effect	sizes,	with	both	measures	show	an	improving	trend	for	the	study	participants	over	time.	This	longitudinal	pattern	of	change	for	the	subscales	of	the	GO-QOL	has	also	been	shown	over	a	24	week	period	in	
a	recent	study	testing	Teprotumumab	for	thyroid-associated	ophthalmology	(Smith	et	al,	2017).	While	both	subscales	of	the	GO-QOL	showed	significant	change	over	time	in	Smith	et	al’s	study,	the	Visual	Function	subscale	was	the	one	with	the	greatest	change	over	time,	as	also	suggested	in	our	data.		The	analysis	with	the	transitional	variables	is	more	equivocal.	The	hypothesized	changes	in	clinical	characteristics	were	generally	associated	with	significant	correlations	for	both	quality	of	life	measures	with	the	transitional	variables	at	the	12	week	time	point.	By	the	48	week	time	point	only	the	GO-QOL	appearance	subscale	recorded	significant	correlations	with	the	T1	(my	eye	condition	causes	me	pain	and	discomfort)	and	T2	(my	eye	condition	limits	my	ability	to	do	the	things	I	want	to	do).	Given	the	focus	of	the	T1	and	T2	variables	on	what	might	be	considered	to	be	issues	more	associated	with	visual	function,	it	is	curious	that	the	observed	correlations	are	with	the	appearance	subscale.	The	Visual	Analogue	Scales	in	the	study	are	more	focused	on	what	might	be	considered	appearance	issues	–	the	perceived	noticeability	and	severity	of	the	TED.	It	is	probably	no	surprise	that	these	were	significantly	correlated	with	the	appearance	subscale	of	the	GO-QOL	at	both	the	12	week	and	48	week	study	time	points.			The	GO-QOL	has	also	demonstrated	discriminant	validity,	with	the	visual	function	subscale	being	able	to	detect	changes	in	groups	identified	by	clinicians	(using	BCCOM	ratings	of	improvement	or	deterioration),	while	both	subscales	could	detect	group	differences	when	based	on	participants’	ratings	of	TED	noticeability	and	severity.	It	has	been	suggested	that	patients with TED overrated the extent to which their appearance was 
affected, while endocrinologists underrated it (Terwee et al, 2003). Of course, the measures 
employed do not necessarily take into account the reference point, i.e. patients are possibly 
comparing themselves prior to TED, or with other people who do not have the disease at all, 
whereas clinicians could be comparing across individuals who have TED. Without 
interviewing the participants and clinicians concerned it is impossible to know. 	Historically	health	care	professionals	have	found	it	difficult	to	engage	with	patient's	concerns	regarding	their	looks	and	body	image	[10],	quantifying	these	concerns	with	a	measure	like	the	GO-QOL	may	help	doctor’s	engagement	with	their	patients	concerns	and	target	therapy	accordingly.	
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